Exploring Biosimilars and IL-1 Inhibitors in Arthritis Treatment

This chapter explores the evolving landscape of spondyloarthritis treatment, focusing on the limited impact of IL-23 inhibition and the emergence of biosimilars. It also reviews a meta-analysis on IL-1 inhibitors for gout management, highlighting effectiveness as well as challenges in approval and cost.